According to Zhitong Finance App News, Libang Pharmaceutical-B (09637) announced that the board of directors has decided to buy back the company's H shares from time to time on the Hong Kong Stock Exchange Limited open market in accordance with the general authorization granted to the company's directors at the extraordinary shareholders' meeting held on August 14, 2026, for a total amount not exceeding HK$100 million (including transaction costs such as brokerage commissions and stamp duties).

The purpose of share repurchases is to protect the company's value and shareholders' interests. After considering (including) the trading performance of H shares, the company's business and financial situation, capital requirements, and the overall interests of shareholders, the board of directors believes that the share repurchase is necessary and reasonable. The board of directors believes that the share repurchase will demonstrate the company's confidence in its own business prospects and future development, and ultimately benefit the company and shareholders. Within the scope of applicable share repurchase authorizations that can be obtained at that time, the company may further repurchase H shares (other than those described above) according to market conditions. The Board believes that the company's current financial resources will enable it to implement share buybacks while maintaining a sound financial position.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.